HRMY
Harmony Biosciences Holdings, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+26/100
Last price
39.36
▼ 0.56 (1.40%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
39.92
Day high
40.35
Day low
38.91
Volume
507.27K
Market cap
$2.29B
P/E (TTM)
12.70
52W range
25.52 – 43.49
Trailing performance
Returnvs SPY
1W
+0.18%
-1.8%
1M
-6.84%
-8.0%
3M
+3.36%
-1.2%
6M
+42.51%
+24.3%
YTD
+5.18%
-9.1%
1Y
+44.28%
+27.9%
3Y
+20.11%
-62.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on HRMY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.25K
Net buying
Buy transactions
3
49.20K shares
Sell transactions
1
33.95K shares
Net transactions
+4
Buys less sells
Sell : buy shares
0.7 : 1
Mixed
Insider-held shares
708.74K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | BUDUR KUMAR Officer |
CONVERSION | 22.95K | $699.94K | Direct |
| Sep 8, 26 | BUDUR KUMAR Officer |
SELL | 33.95K | $1.45M | Direct |
| May 1, 26 | BUDUR KUMAR Officer |
— | 18.75K | — | Direct |
| Apr 7, 26 | ZAESKE ADAM H. Officer |
— | 7.50K | — | Direct |
| Jan 26, 26 | KAPADIA SANDIP Chief Financial Officer |
SELL | 3.75K | $139.17K | Direct |
| Jan 23, 26 | DAYNO JEFFREY M Chief Executive Officer |
— | 23.50K | — | Direct |
| Jan 23, 26 | KAPADIA SANDIP Chief Financial Officer |
— | 8.54K | — | Direct |
| Jan 23, 26 | SERAFIN ANDREW Officer |
— | 5.10K | — | Direct |
| Jan 23, 26 | BUDUR KUMAR Officer |
— | 4.85K | — | Direct |
| Jan 15, 26 | KAPADIA SANDIP Chief Financial Officer |
SELL | 20.96K | $752.83K | Direct |
| Dec 12, 25 | DAYNO JEFFREY M Chief Executive Officer |
CONVERSION | 20.00K | $164.40K | Direct |
| Dec 12, 25 | DAYNO JEFFREY M Chief Executive Officer |
SELL | 25.93K | $1.04M | Direct |
| Dec 5, 25 | KAPADIA SANDIP Chief Financial Officer |
CONVERSION | 20.00K | $580.60K | Direct |
| Dec 5, 25 | KAPADIA SANDIP Chief Financial Officer |
SELL | 20.00K | $790.90K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUDUR KUMAR |
Officer | 13.12K | Conversion of Exercise of derivative security |
DAYNO JEFFREY M |
Chief Executive Officer | 7.35K | Conversion of Exercise of derivative security |
DIERKS JEFFREY G |
Officer | 0 | Conversion of Exercise of derivative security |
KAPADIA SANDIP |
Chief Financial Officer | 24.52K | Sale |
MARSHMAN FUND TRUST II |
Beneficial Owner of more than 10% of a Class of Security | 6.05M | Sale |
SERAFIN ANDREW |
Officer | 1.47K | Conversion of Exercise of derivative security |
VALOR EQUITY PARTNERS |
Beneficial Owner of more than 10% of a Class of Security | 6.62M | Sale |
VALOR IV PHARMA HOLDINGS L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | 6.62M | Sale |
ZAESKE ADAM H. |
Officer | 4.33K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.29B
Enterprise value$1.78B
Revenue (TTM)$959.90M
Gross profit$723.99M
EBITDA$255.99M
Net income$181.27M
EPS (TTM)$3.10
Free cash flow$182.84M
Total cash$667.79M
Total debt$160.19M
Book value / share$17.19
Shares outstanding58.24M
Float52.09M
Short % of float10.62%
Dividend yield0.00%
Beta (5Y)1.01
Valuation & profitability ratios
Trailing P/E12.70
Forward P/E5.62
PEG ratio—
Price / sales—
Price / book2.29
EV / revenue1.86
EV / EBITDA6.97
Gross margin75.42%
Operating margin34.18%
Profit margin18.88%
Return on equity20.46%
Return on assets11.62%
Debt / equity16.03
Current ratio3.48
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $868.45M | $714.73M | $582.02M | $437.86M | +21.5% |
| Operating revenue | $868.45M | $714.73M | $582.02M | $437.86M | +21.5% |
| Cost of revenue | $198.34M | $156.81M | $121.24M | $83.48M | +26.5% |
| Gross profit | $670.11M | $557.92M | $460.79M | $354.37M | +20.1% |
| Research & development | $189.59M | $145.82M | $76.06M | $70.89M | +30.0% |
| Selling, general & admin | $272.05M | $221.27M | $192.69M | $163.30M | +22.9% |
| Total operating expense | $461.64M | $367.09M | $268.76M | $234.19M | +25.8% |
| Operating income | $208.47M | $190.83M | $192.03M | $120.19M | +9.2% |
| Net interest income | $7.28M | $1.05M | -$9.03M | -$15.67M | +595.5% |
| Pre-tax income | $215.06M | $191.80M | $173.40M | $104.69M | +12.1% |
| Tax provision | $56.38M | $46.31M | $44.54M | -$76.78M | +21.7% |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | +9.1% |
| Net income to common | $158.69M | $145.49M | $128.85M | $181.47M | +9.1% |
| Basic EPS | 2.76 | 2.56 | 2.17 | 3.07 | +7.8% |
| Diluted EPS | 2.71 | 2.51 | 2.13 | 2.97 | +8.0% |
| EBIT | $229.71M | $209.30M | $197.15M | $123.48M | +9.8% |
| EBITDA | $255.05M | $233.41M | $221.51M | $146.87M | +9.3% |
| Basic shares | 57.49M | 56.89M | 59.47M | 59.17M | +1.1% |
| Diluted shares | 58.54M | 57.87M | 60.37M | 61.10M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $752.50M | $453.00M | $311.66M | $243.78M | — | +66.1% |
| Cash & short-term investments | $775.34M | $467.19M | $353.46M | $323.12M | — | +66.0% |
| Accounts receivable | $96.79M | $83.03M | $74.14M | $54.74M | — | +16.6% |
| Inventory | $5.36M | $7.20M | $5.36M | $4.30M | — | -25.6% |
| Total current assets | $907.01M | $579.25M | $451.07M | $400.29M | — | +56.6% |
| Property, plant & equipment | — | $1.26M | $371.00K | $573.00K | $820.00K | — |
| Goodwill & intangibles | $89.42M | $113.26M | $137.11M | $160.95M | — | -21.1% |
| Total assets | $1.27B | $999.20M | $811.45M | $673.87M | — | +27.3% |
| Total current liabilities | $252.13M | $175.08M | $163.78M | $78.88M | — | +44.0% |
| Current debt | $20.00M | $16.25M | $15.00M | $2.00M | — | +23.1% |
| Long-term debt | $143.66M | $163.02M | $178.57M | $189.65M | — | -11.9% |
| Total debt | $163.66M | $179.27M | $193.57M | $191.65M | — | -8.7% |
| Total liabilities | $401.41M | $340.05M | $344.46M | $271.03M | — | +18.0% |
| Retained earnings | $160.90M | $2.22M | -$143.28M | -$272.13M | — | +7,161.0% |
| Shareholder equity | $870.22M | $659.15M | $466.99M | $402.84M | — | +32.0% |
| Working capital | $654.88M | $404.17M | $287.29M | $321.40M | — | +62.0% |
| Net tangible assets | $780.80M | $545.89M | $329.88M | $241.88M | — | +43.0% |
| Shares issued | 57.73M | 57.14M | 56.77M | 59.62M | — | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | +9.1% |
| Depreciation & amortisation | $25.34M | $24.11M | $24.36M | $23.39M | +5.1% |
| Stock-based compensation | $44.90M | $42.60M | $31.70M | $26.17M | +5.4% |
| Change in working capital | $91.82M | -$7.32M | $35.03M | -$4.11M | +1,354.2% |
| Operating cash flow | $348.20M | $219.82M | $219.39M | $144.47M | +58.4% |
| Capital expenditure | -$310.00K | -$1.15M | -$312.00K | -$172.00K | +73.1% |
| Investing cash flow | -$39.65M | -$67.48M | -$46.44M | -$141.83M | +41.2% |
| Share buybacks | $0 | $0 | -$100.00M | $0 | — |
| Financing cash flow | -$9.05M | -$11.00M | -$105.55M | $6.84M | +17.7% |
| Free cash flow | $347.89M | $218.67M | $219.07M | $144.29M | +59.1% |
| End cash position | $752.77M | $453.27M | $311.93M | $244.53M | +66.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $261.28M | $215.39M | $243.78M | $239.46M | $200.49M | +21.3% |
| Operating revenue | $261.28M | $215.39M | $243.78M | $239.46M | $200.49M | +21.3% |
| Cost of revenue | $63.20M | $44.51M | $68.55M | $59.65M | $38.15M | +42.0% |
| Gross profit | $198.08M | $170.88M | $175.23M | $179.81M | $162.34M | +15.9% |
| Research & development | $46.60M | $69.38M | $49.93M | $54.96M | $50.16M | -32.8% |
| Selling, general & admin | $62.17M | $64.20M | $86.74M | $59.36M | $64.00M | -3.2% |
| Total operating expense | $108.77M | $133.58M | $136.67M | $114.32M | $114.16M | -18.6% |
| Operating income | $89.32M | $37.29M | $38.56M | $65.49M | $48.18M | +139.5% |
| Net interest income | $4.00M | $2.52M | $2.31M | $2.11M | $1.65M | +58.6% |
| Pre-tax income | $93.27M | $39.69M | $40.76M | $67.49M | $49.64M | +135.0% |
| Tax provision | $17.83M | $7.20M | $18.27M | $16.63M | $9.86M | +147.7% |
| Net income | $75.43M | $32.49M | $22.49M | $50.87M | $39.78M | +132.2% |
| Net income to common | $75.43M | $32.49M | $22.49M | $50.87M | $39.78M | +132.2% |
| Basic EPS | 1.30 | 0.56 | 0.39 | 0.88 | 0.69 | +132.1% |
| Diluted EPS | 1.28 | 0.55 | 0.38 | 0.87 | 0.68 | +132.7% |
| EBIT | $96.33M | $42.92M | $44.31M | $71.11M | $53.28M | +124.4% |
| EBITDA | $102.30M | $48.89M | $51.74M | $77.08M | $59.25M | +109.3% |
| Basic shares | 57.93M | 57.82M | 57.63M | 57.55M | 57.47M | +0.2% |
| Diluted shares | 58.76M | 58.78M | 58.70M | 58.72M | 58.43M | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $549.77M | $589.40M | $752.50M | $647.00M | $546.05M | — | -6.7% |
| Cash & short-term investments | $667.79M | $640.92M | $775.34M | $672.58M | $565.27M | — | +4.2% |
| Accounts receivable | $111.00M | $108.22M | $96.79M | $100.65M | $92.98M | — | +2.6% |
| Inventory | $6.36M | $5.28M | $5.36M | $6.88M | $6.10M | — | +20.4% |
| Total current assets | $814.33M | $778.82M | $907.01M | $838.80M | $691.35M | — | +4.6% |
| Property, plant & equipment | — | — | — | $1.44M | $1.38M | $1.38M | — |
| Goodwill & intangibles | $77.50M | $83.46M | $89.42M | $95.38M | $101.34M | — | -7.1% |
| Total assets | $1.37B | $1.27B | $1.27B | $1.21B | $1.11B | — | +8.0% |
| Total current liabilities | $234.07M | $217.34M | $252.13M | $223.40M | $180.13M | — | +7.7% |
| Current debt | $20.00M | $20.00M | $20.00M | $20.00M | $18.75M | — | 0.0% |
| Long-term debt | $133.96M | $138.81M | $143.66M | $148.51M | $153.34M | — | -3.5% |
| Total debt | $153.96M | $158.81M | $163.66M | $168.51M | $172.09M | — | -3.1% |
| Total liabilities | $373.84M | $361.48M | $401.41M | $373.10M | $334.93M | — | +3.4% |
| Retained earnings | $268.82M | $193.39M | $160.90M | $138.42M | $87.55M | — | +39.0% |
| Shareholder equity | $999.24M | $910.35M | $870.22M | $835.12M | $773.08M | — | +9.8% |
| Working capital | $580.26M | $561.48M | $654.88M | $615.40M | $511.22M | — | +3.3% |
| Net tangible assets | $921.75M | $826.89M | $780.80M | $739.74M | $671.74M | — | +11.5% |
| Shares issued | 58.12M | 57.87M | 57.73M | 57.60M | 57.54M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $75.43M | $32.49M | $22.49M | $50.87M | $39.78M | — | +132.2% |
| Depreciation & amortisation | $5.97M | $5.97M | $7.43M | $5.97M | $5.97M | — | 0.0% |
| Stock-based compensation | $9.34M | $10.62M | $9.97M | $10.97M | $11.46M | — | -12.1% |
| Change in working capital | $4.25M | -$49.63M | $74.04M | $30.14M | $13.50M | — | +108.6% |
| Operating cash flow | $92.43M | $27.76M | $126.15M | $108.73M | $79.33M | — | +233.0% |
| Capital expenditure | — | — | -$107.00K | -$71.00K | -$4.00K | -$128.00K | — |
| Investing cash flow | -$131.50M | -$183.65M | -$17.63M | -$4.79M | -$19.59M | — | +28.4% |
| Financing cash flow | -$558.00K | -$7.22M | -$3.02M | -$3.00M | -$2.69M | — | +92.3% |
| Free cash flow | $92.43M | $27.76M | $126.04M | $108.66M | $79.32M | — | +233.0% |
| End cash position | $550.04M | $589.67M | $752.77M | $647.27M | $546.32M | — | -6.7% |
Options analytics
Put / call volume
16.58
Put-heavy session
Put / call open interest
0.70
Positioning, not flow
Max pain
35.00
-11.1% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
31
Contracts, this expiry
Put volume
514
Contracts, this expiry
Heaviest call OI
40.00
986 contracts
Heaviest put OI
20.00
1.01K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.15 | 1.50 | +30.6% |
| Mar 2026 | 0.93 | 0.79 | -15.9% |
| Dec 2025 | 1.07 | 0.57 | -46.5% |
| Sep 2025 | 0.86 | 1.08 | +25.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.47 | 2 | $274.55M | +14.6% |
| Next quarter | 1.53 | 2 | $282.74M | +16.0% |
| Current year | 5.22 | 2 | $1.03B | +18.7% |
| Next year | 7.00 | 2 | $1.17B | +13.0% |
Analyst targets & ownership
Mean target$47.64
High target$70.00
Low target$30.00
Implied upside21.03%
Analyst count11
ConsensusBUY
Strong buy / Buy2 / 5
Hold3
Sell / Strong sell0 / 1
Held by insiders1.22%
Held by institutions99.62%
Institutions holding449
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
39.99
-1.59% from price
SMA 20
40.92
-3.82% from price
SMA 50
39.70
-0.85% from price
SMA 100
36.79
+7.00% from price
SMA 200
34.65
+13.60% from price
EMA 12
40.15
-1.97% from price
EMA 26
40.29
-2.31% from price
EMA 50
39.44
-0.19% from price
RSI (14)
43.1
Neutral
MACD (12,26,9)
-0.14
Hist -0.34
ATR (14)
1.37
3.47% of price
Realised vol 30D
27.2%
Annualised
Bollinger upper
43.13
20, 2σ
Bollinger lower
38.72
20, 2σ
50 / 200 cross
Golden
39.70 vs 34.65
Trend bias
Above 200
+13.60%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.52
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
27.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.5%
Peak to trough
Max drawdown 5Y
-68.5%
Peak to trough
ATR 14
1.37
3.47% of price
Beta (reported)
1.01
5Y monthly, from filing
Short interest
Shares short
4.63M
Prior 4.14M
Change vs prior
+11.9%
Shorts adding
% of float
10.62%
Elevated
% of shares out
7.95%
Against total outstanding
Days to cover
5.7
Crowded exit
Float
52.09M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 26, 26 | Wolfe Research | INITIATED | — | Outperform |
| Aug 5, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Aug 4, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 31, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 30, 26 | Deutsche Bank | MAINTAINED | Hold | Hold |
| May 8, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Feb 25, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Feb 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 25, 26 | B of A Securities | MAINTAINED | Underperform | Underperform |
| Feb 25, 26 | Needham | MAINTAINED | Buy | Buy |
| Feb 11, 26 | UBS | DOWNGRADE | Buy | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-04-14
Proxy Statements
DEF 14A · 2026-04-03
Corporate Changes & Voting Matters
8-K · 2026-04-02
Periodic Financial Reports
10-K · 2026-02-24
Headlines
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Zacks · 22h ago
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Zacks · 1d ago
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
GlobeNewswire · 6d ago
Deutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold Rating
MT Newswires · 6d ago
Harmony Biosciences Holdings Insider Sold Shares Worth $1,655,416, According to a Recent SEC Filing
MT Newswires · 19d ago
Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing
MT Newswires · 28d ago
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Zacks · 33d ago
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Zacks · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.